fibroblast cells  (ATCC)

Journal: Frontiers in Bioengineering and Biotechnology

Article Title: Using silica nanoparticles to deliver antibiotics for treating Gram-positive bacterial infections in a 3D-bioprinted dermal model

doi: 10.3389/fbioe.2026.1737616

Figure Lengend Snippet: 3D-bioprinted CAD file that was used to print the fibroblast construct. The final dome-shaped structure had a 1.0 cm diameter and six layers of fibers with an average width of ≈1.1 cm and a height of ≈0.7 cm (Aspect studio software, V1.2.59.0, Aspect Biosystems, Vancouver, BC, Canada).

Article Snippet: Fibroblast cells (Primary Dermal Fibroblast Normal; Human, Neonatal (HDFn), ATCC ® PCS-201-010TM—Neonatal foreskin fibroblasts, male donor) were used.

Techniques: Construct, Software

Journal: Frontiers in Bioengineering and Biotechnology

Article Title: Using silica nanoparticles to deliver antibiotics for treating Gram-positive bacterial infections in a 3D-bioprinted dermal model

doi: 10.3389/fbioe.2026.1737616

Figure Lengend Snippet: Schematic showing 3D bioprinting of human fibroblasts with the antibiotic clindamycin in SiNPs and S. epidermidis . The same setup was used to test tetracycline-loaded SiNPs and S. aureus .

Article Snippet: Fibroblast cells (Primary Dermal Fibroblast Normal; Human, Neonatal (HDFn), ATCC ® PCS-201-010TM—Neonatal foreskin fibroblasts, male donor) were used.

Techniques:

Journal: Frontiers in Bioengineering and Biotechnology

Article Title: Using silica nanoparticles to deliver antibiotics for treating Gram-positive bacterial infections in a 3D-bioprinted dermal model

doi: 10.3389/fbioe.2026.1737616

Figure Lengend Snippet: S. aureus bacterial fluorescence imaging using BacLight ® . Bacteria were imaged in LB broth after the addition of SiNP-loaded clindamycin 500 mg/mL: (a) green emission (live bacteria) and (b) red emission (dead bacteria). Fibroblast treatment of bare SiNPs: (c) green emission (live bacteria) and (d) red emission (dead bacteria). Untreated fibroblast constructs: (e) green emission (live bacteria) and (f) red emission (dead bacteria). Images (a–f) are from the same location with different fluorescence.

Article Snippet: Fibroblast cells (Primary Dermal Fibroblast Normal; Human, Neonatal (HDFn), ATCC ® PCS-201-010TM—Neonatal foreskin fibroblasts, male donor) were used.

Techniques: Fluorescence, Imaging, Bacteria, Construct

Journal: Frontiers in Bioengineering and Biotechnology

Article Title: Using silica nanoparticles to deliver antibiotics for treating Gram-positive bacterial infections in a 3D-bioprinted dermal model

doi: 10.3389/fbioe.2026.1737616

Figure Lengend Snippet: Imaging of 3D-bioprinted construct of fibroblasts infected with S. epidermidis (AH852) and treated with SiNP-loaded clindamycin 500 mg/mL under three conditions: pre-infection and pre-treatment (control group, with only fibroblasts 3D bioprinted), post-infection and pre-treatment (only S. epidermidis with GFP (green dots in the image) inoculation in the 3D-bioprinted construct, but with no treatment), and post-infection and post-treatment ( S. epidermidis with GFP (green dots in the image) inoculation in the 3D-bioprinted construct treated with SiNP-loaded clindamycin 500 mg/mL).

Article Snippet: Fibroblast cells (Primary Dermal Fibroblast Normal; Human, Neonatal (HDFn), ATCC ® PCS-201-010TM—Neonatal foreskin fibroblasts, male donor) were used.

Techniques: Imaging, Construct, Infection, Control

Journal: Frontiers in Bioengineering and Biotechnology

Article Title: Using silica nanoparticles to deliver antibiotics for treating Gram-positive bacterial infections in a 3D-bioprinted dermal model

doi: 10.3389/fbioe.2026.1737616

Figure Lengend Snippet: Investigations in the “dermis” model of 3D-bioprinted construct inoculated with S. epidermidis and treated with SiNP-loaded clindamycin 500 mg/mL. (a) CFU counts in the pre-infection and pre-treatment condition, showing the higher S. epidermidis CFUs (before inoculating them in the 3D-bioprinted construct) than in the fibroblast HDFn media. (b) CFU counts in the post-infection and pre-treatment conditions show higher S. epidermidis growth over time. (c) CFU counts in the post-infection and post-treatment conditions highlight the effectiveness of SiNP-loaded clindamycin 500 mg/mL treatment against S. epidermidis in the 3D-bioprinted construct. (d) Growth curve of the S. epidermidis (AH852) showing its growth over time. (e) S. epidermidis bacterial imaging using BacLight® fluorescence detection. Bacteria were imaged in LB broth after the addition of SiNP-loaded clindamycin 500 mg/mL, green fluorescent protein (GFP): live bacteria (green dots in the image), Texas Red: dead bacteria (red dots in the image). The absence of red dots indicates that the SiNP-loaded clindamycin 500 mg/mL was an effective treatment against S. epidermidis in the 3D-bioprinted construct, in that it prevented the S. epidermidis from forming colonies or biofilms in the 3D-bioprinted construct. Images on (e) are the same spot with different fluorescence (one-way ANOVA and Tukey post-test; *: p < 0.05).

Article Snippet: Fibroblast cells (Primary Dermal Fibroblast Normal; Human, Neonatal (HDFn), ATCC ® PCS-201-010TM—Neonatal foreskin fibroblasts, male donor) were used.

Techniques: Construct, Infection, Imaging, Fluorescence, Bacteria

Journal: Scientific Reports

Article Title: Chitosan-dextran sulfate nanocapsules for enhanced tigecycline efficacy against non-typhoidal Salmonella enterica

doi: 10.1038/s41598-026-35229-7

Figure Lengend Snippet: TGC and/or unloaded CD NPs ameliorated the S. Typhimurium infected group induced histopathological alterations in mice’s liver tissues. Representative photomicrographs of the H&E-stained hepatic tissue sections showing the control (A), S. Typhimurium infected group (C), TGC (E), unloaded CD NPs (G), CD-TGC groups (I) and their respective higher magnifications (B, D, F, H, and J). A, B: control group displaying normal central vein (CV), hepatic cords (HC) with hepatocytes of eosinophilic granular cytoplasm (EC), rounded central single (SN) or double vesicular nuclei (DN), and kupffer cells (KC). C, D: S. Typhimurium infected group demonstrating multiple areas of variable-sized necrotic areas (NA) of coagulative necrosis (CN), severely dilated and congested sinusoid (SDS) with Kupffer cell hyperplasia (KCH). E, F: TGC group displaying moderately sized necrotic areas (MNA), moderately dilated and congested sinusoids (MDS), moderately hyperplastic Kupffer’s cells (MKC), interstitial mononuclear cell infiltration (MI), fibroblast proliferation (FP), and regenerated hepatocytes of stippling basophilic cytoplasm (BC) and pale nuclei (PN). G, H: unloaded CD NPs group showing a few scattered minute necrotic areas (mNA), intense mononuclear cell infiltration (IMI) around the portal area, and apparently normal hepatocytes (NH). I, J: CD-TGC group showed normal hepatocytes (NH), few dilated blood vessels (DBV), and a few interstitial lymphocytic aggregates (FL). Scale bars = 100 μm in A, C, E, G, I; and = 20 μm in B, D, F, H, and J. K: Bar charts demonstrate the statistical analysis of the comparative quantification of the hepatic injury scores in all studied groups. Bars carrying different superscript letters (a, b, c, d, and e) are significantly different as analyzed by the one-way ANOVA test, followed by the multiple comparisons by Duncan’s Post-hoc test ( p < 0.05). Values are the mean of 6 mice per group ± S.E.M.

Article Snippet: BJ normal human foreskin primary fibroblast cell line (ATCC CRL-2522) was used for studying safety of CD-TGC nanocapsules.

Techniques: Infection, Staining, Control